Key Highlights
- Tim Sullivan, Ph.D. appointed as Chief Business Officer at Infinimmune.
- Sullivan to lead corporate and business development, strategic planning.
- Brings decades of experience from roles at Spring Discovery, Arcus Biosciences, and Pfizer.
- Infinimmune is pioneering fully human antibody therapies.
Source: Business Wire
Notable Quotes
- “We’re thrilled to have Tim lead Infinimmune’s business development efforts, driving strategic growth initiatives and fostering key partnerships to advance our mission of developing fully human antibody therapies.” — Wyatt McDonnell, CEO & Co-Founder at Infinimmune
- “I am excited to join Infinimmune at such a dynamic time. The company’s commitment to pioneering advances in antibody development is truly inspiring, and I look forward to contributing to its continued success by leading our business development initiatives.” — Tim Sullivan, Ph.D., Chief Business Officer at Infinimmune
SoHC's Take
Tim Sullivan’s extensive experience in leading business development efforts across prominent biotechnology companies, including Spring Discovery and Arcus Biosciences, positions him well to drive Infinimmune’s growth. His background in securing strategic partnerships and advancing innovation pipelines will likely catalyze Infinimmune’s mission of delivering fully human antibody therapies to market.
